Search Results for: lxrp

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced the results of the 2020 Annual and Special Meeting (the “Meeting”). According to the update, the Meeting was held at 1:00 p.m. (Pacific Time) on June 23, 2020, whereby there were 47,819,789 shares of the Company represented in person … Continue reading “QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Announces Results from 2020 Annual and Special Meeting”

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced its submission of a grant application to the U.S. National Institutes of Health (“NIH”) entitled “In vitro and in vivo animal exploratory pharmacokinetic and preliminary efficacy modelling of select orally administered antiviral compounds following DehydraTECH formulation enhancement.” According to … Continue reading “QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Applies for NIH Grant to Support COVID-19 Therapy Studies, Receives Expanded Health Canada License”

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, on Monday announced that it has retained PCG Advisory, Inc. (“PCG”) of New York, to provide investor relations and digital marketing services to the Company in compliance with regulatory guidelines. According to the update, PCG’s sectors of deepest experience include life … Continue reading “QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Engages PCG of New York for IR and Digital Marketing Services”

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, on Monday announced the close of its private placement financing. The company issued a total amount of 8,028,254 shares of its common stock along with common stock purchase warrants to purchase up to 8,028,254 shares of its common stock for gross proceeds … Continue reading “QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Closes Private Placement”

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced its entry into definitive agreements with certain qualified investors for the sale of 8,978,260 shares (“Shares”) of its common stock along with common stock purchase warrants (“Warrants”) to purchase up to 8,978,260 shares of its common stock in a … Continue reading “QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Announces Over US$2 Million Private Placement”

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced its receipt of a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”) for a new patent. According to the update, the new patent provides additional claims that protect the use of its DehydraTECH(TM) technology together with … Continue reading “QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Announces Notice of Allowance for New Patent, Issuance of Stock Options Under Equity Incentive Plan”

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced that it has filed an important new patent application in the United States describing the use of its DehydraTECH(TM) technology for the delivery of antiviral drugs. According to the update, the technology would potentially be used to improve treatment … Continue reading “QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Files New Patent Application for DehydraTECH Technology in Delivery of Antiviral Drugs”

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, on Tuesday announced that its Chief Executive Officer, Chris Bunka, will present live at LifeSciencesInvestorForum.com on March 26. According to the update, Bunka’s presentation is scheduled to begin at 12:00 PM ET. The live, interactive online event invites investors to ask the … Continue reading “QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) to Webcast Live at March 26 Life Sciences Investor Forum”

Life Sciences Investor Forum today announced the schedule for its inaugural event for both public and private companies, investors and worldwide industry professionals. The one-day event is kicking off on Thursday, March 26 with the first live webcast at 9:30 AM ET. Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, … Continue reading “QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) to Participate in Life Sciences Investor Forum’s Virtual Conference”

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced expansion of the scope and activities of its 100%-owned subsidiary Lexaria Pharmaceutical Corp. According to the update, Lexaria Pharmaceutical will investigate how the company’s patented DehydraTECH(TM) drug delivery technology could enhance delivery and effectiveness of certain antiviral drugs in … Continue reading “QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Announces Expansion of Pharmaceutical Division to Include Lipophilic Antiviral Active Molecules for COVID-19 Treatment”